Eosinophilic esophagitis: Pathophysiology and optimal management

Current Gastroenterology Reports

Volumn 11, Issue 3, 2009, Pages 175-181

  Garrean, Carol ^a   Hirano, Ikuo ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; ELECARE; EOTAXIN 3; FLUTICASONE; FLUTICASONE PROPIONATE; IMMUNOGLOBULIN E ANTIBODY; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; MEPOLIZUMAB; MONTELUKAST; NEOCATE; NUTRACEUTICAL; OMALIZUMAB; PLACEBO; PREDNISONE; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ADRENAL SUPPRESSION; CLINICAL TRIAL; CUSHINGOID SYNDROME; DEGRANULATION; DIET RESTRICTION; DIET THERAPY; DRUG INDUCED HEADACHE; ELEMENTAL DIET; EOSINOPHIL COUNT; EOSINOPHILIC ESOPHAGITIS; ESOPHAGUS CANDIDIASIS; ESOPHAGUS DILATATION; ESOPHAGUS PERFORATION; FOOD ALLERGY; GASTROESOPHAGEAL REFLUX; HUMAN; LACERATION; LEUKOCYTE MIGRATION; LIFESTYLE MODIFICATION; MAST CELL; MYALGIA; NAUSEA; NONHUMAN; OSTEOLYSIS; PATCH TEST; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRICK TEST; REVIEW; SEROLOGY; SIDE EFFECT; TH2 CELL; THORAX PAIN; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS; BALLOON DILATATION; DIAGNOSIS, DIFFERENTIAL; EOSINOPHILIA; ESOPHAGITIS; ESOPHAGOSCOPY; GASTROESOPHAGEAL REFLUX; HISTAMINE ANTAGONISTS; HUMANS; HYPERSENSITIVITY; INTESTINAL MUCOSA; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 66149098229     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-009-0028-0     Document Type: Review

References (42)

1. Furuta GT, Liacouras CA, Collins MH, et al.; First International Gastrointestinal Eosinophil Research Symposium (FIGERS) Subcommittees: Eosinophilic esophagitis in children and adults: A systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007, 133:1342-1363.
2. Prasad GA, Talley NJ, Romero Y, et al.: Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: A prospective study. Am J Gastroenterol 2007, 102:2627-2632.
3. Dellon ES, Aderoju A, Woosley JT, et al.: Variability in diagnostic criteria for eosinophilic esophagitis: A systematic review. Am J Gastroenterol 2007, 102:2300-2313.
4. Gonsalves N, Policarpio-Nicolas M, Zhang Q, et al.: Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006, 64:313-319.
5. Shah A, Kagalwalla AF, Gonsalves N, et al.: Histopathologic variability in children with eosinophilic esophagitis. Am J Gastroenterol 2009, 104: 716-721.
6. Blanchard C, Wang N, Rothenberg ME: Eosinophilic esophagitis: pathogenesis, genetics, and therapy. J Allergy. Clin Immunol 2006, 118:1054-1059.
7. Mishra A, Rothenberg ME: Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology 2003, 125:1419-1427.
8. Blanchard C, Wang N, Stringer KF, et al.: Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 2006, 116:536-547.
9. Bullock JZ, Villanueva JM, Blanchard C, et al.: Interplay of adaptive th2 immunity with eotaxin-3/c-C chemokine receptor 3 in eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2007, 45:22-31.
10. Rothenberg ME, Mishra A, Brandt EB, et al.: Gastrointestinal eosinophils. Immunol Rev 2001, 179:139-155.
11. Fryer AD, Stein LH, Nie Z, et al.: Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. J Clin Invest 2006, 116:228-236.
12. Liacouras CA, Spergel JM, Ruchelli E, et al.: Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol 2005, 3:1198-1206.
13. Dauer EH, Freese DK, El-Youssef M, et al.: Clinical characteristics of eosinophilic esophagitis in children. Ann Otol Rhinol Laryngol 2005, 114: 827-833.
14. Spergel JM, Beausoleil JL, Mascarenhas M, et al.: The use of skin prick tests and patch tests to identify causative foods in eosinophilic esophagitis. J Allergy Clin Immunol 2002, 109: 363-368.
15. Spergel JM, Andrews T, Brown-Whitehorn TF, et al.: Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch tests. Ann Allergy Asthma Immunol 2005, 95:336-343.
16. Spechler SJ, Genta RM, Souza RF: Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol 2007, 102:1301-1306.
17. Bhattacharya B, Carlsten J, Sabo E, et al.: Increased expression of eotaxin-3 distinguishes between eosinophilic esophagitis and gastroesophageal reflux disease. Hum Pathol 2007, 38:1744-1753.
18. Ngo P, Furuta GT, Antonioli DA, et al.: Eosinophils in the esophagus-peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol 2006, 101:1666-1670.
19. Garrean CP GN, Hirano I: Comparison of demographic, endoscopic and histologic features in EoE patients with and without GERD. Gastroenterology 2008, 134(Suppl 1):A288.
20. Dranove JE, Horn DS, Davis MA, et al.: Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. J Pediatr 2009, 154:96-100.
21. Schaefer ET, Fitzgerald JF, Molleston JP, et al.: Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: A randomized trial in children. Clin Gastroenterol Hepatol 2008, 6:165-173.
22. Faubion WA Jr, Perrault J, Burgart LJ, et al.: Treatment of eosinophilic esophagitis with inhaled corticosteroids. J Pediatr Gastroenterol Nutr 1998, 27:90-93.
23. Konikoff MR, Noel RJ, Blanchard C, et al.: A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006, 131:1381-1391.
24. Arora AS, Perrault J, Smyrk TC: Topical corticosteroid treatment of dysphagia due to eosinophilic esophagitis in adults. Mayo Clin Proc 2003, 78:830-835.
25. Remedios M, Campbell C, Jones DM, et al.: Eosinophilic esophagitis in adults: Clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. Gastrointest Endosc 2006, 63:3-12.
26. Aceves SS, Bastian AF, Newbury RO, et al.: Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. Am J Gastroenterol 2007, 102: 2271-2279; quiz 2280.
27. Straumann A, Degen L, Felder S, et al.: Budesonide as induction treatment for active eosinophilic esophagitis in adolescents and adults: a randomized, double-blind, placebo-controlled study (Bee-I trial). Gastroenterology 2008, 134(Suppl 1):A104.
28. Arora AS, Yamazaki KA Eosinophilic esophagitis: asthma of the esophagus? Clin Gastroenterol Hepatol 2004, 2:523-530.
29. Attwood SE, Lewis CJ,ABronder CS, et al.: Eosinophilic oesophagitis: a novel treatment using montelukast. Gut 2003, 52:181-185.
30. Gupta SK, Peters-Golden M, Fitzgerald JF, et al.: Cysteinyl leukotriene levels in esophageal mucosal biopsies of children with eosinophilic inflammation: Are they all the same? Am J Gastroenterol 2006, 101:1125-1128.
31. Stein ML, Collins MH, Villanueva JM, et al.: Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 2006, 118:1312-1319.
32. Foroughi S, Foster B, Kim N, et al.: Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 2007, 120:594-601.
33. Straumann A BC, Conus, S, et al.: Infliximab, a monoclonal antibody to TNF-a, for severe eosinophilic esophagitis in adults: A prospective, translational pilot-study. Gastroenterology 2008, 134(Suppl 1):A105.
34. Kelly KJ, Lazenby AJ, Rowe PC, et al.: Eosinophilic esophagitis attributed to gastroesophageal reflux: Improvement with an amino acid-based formula. Gastroenterology 1995, 109:1503-1512.
35. Kagalwalla AF, Sentongo TA, Ritz S, et al.: Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol 2006, 4:1097-1102.
36. Gonsalves N, Yang G, Hirano I: A prospective clinical trial of six food elimination diet and reintroduction of causative agents in adults with eosinophilic esophagitis (EE). Gastroenterology 2008, 134(Suppl 1):A104.
37. Attwood SE, Smyrk TC, Demeester TR, et al.: Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci 1993, 38:109-116.
38. Potter JW, Saeian K, Staff D, et al.: Eosinophilic esophagitis in adults: An emerging problem with unique esophageal features. Gastrointest Endosc 2004, 59:355-361.
39. Schoepfer AM, Gschossmann J, Scheurer U, et al.: Esophageal strictures in adult eosinophilic esophagitis: Dilation is an effective and safe alternative after failure of topical corticosteroids. Endoscopy 2008, 40:161-164.
40. Straumann A, Spichtin HP, Grize L, et al.: Natural history of primary eosinophilic esophagitis: A follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003, 125:1660-1669.
41. Cohen MS, Kaufman A, DiMarino AJ Jr, et al.: Eosinophilic esophagitis presenting as spontaneous esophageal rupture (Boerhaave's syndrome). Clin Gastroenterol. Hepatol 2007, 5:A24.
42. Gonsalves N, Hirano I: Safety and response of esophageal dilation in adults with eosinophilic esophagitis (EE): A single center experience of 81 patients. Gastroenterology 2007, 132(Suppl 2):A607.